Lineage Cell (Israel) Market Value
| BTX Stock | ILS 212.90 8.70 3.93% |
| Symbol | Lineage |
Lineage Cell 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Lineage Cell's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Lineage Cell.
| 06/10/2023 |
| 12/01/2024 |
If you would invest 0.00 in Lineage Cell on June 10, 2023 and sell it all today you would earn a total of 0.00 from holding Lineage Cell Therapeutics or generate 0.0% return on investment in Lineage Cell over 540 days. Lineage Cell is related to or competes with Enlivex Therapeutics, Compugen, Purple Biotech, BioLine RX, Clal Biotechnology, and Evogene. BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treat... More
Lineage Cell Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Lineage Cell's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Lineage Cell Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 30.72 | |||
| Value At Risk | (12.65) | |||
| Potential Upside | 6.36 |
Lineage Cell Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lineage Cell's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Lineage Cell's standard deviation. In reality, there are many statistical measures that can use Lineage Cell historical prices to predict the future Lineage Cell's volatility.| Risk Adjusted Performance | (0.1) | |||
| Jensen Alpha | (0.64) | |||
| Total Risk Alpha | (1.63) | |||
| Treynor Ratio | 0.8546 |
Lineage Cell Therapeutics Backtested Returns
Lineage Cell Therapeutics has Sharpe Ratio of -0.15, which conveys that the firm had a -0.15% return per unit of risk over the last 3 months. Lineage Cell exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Lineage Cell's Risk Adjusted Performance of (0.1), standard deviation of 5.26, and Mean Deviation of 3.59 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of -0.88, which conveys possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Lineage Cell are expected to decrease slowly. On the other hand, during market turmoil, Lineage Cell is expected to outperform it slightly. At this point, Lineage Cell Therapeutics has a negative expected return of -0.83%. Please make sure to verify Lineage Cell's accumulation distribution, and the relationship between the value at risk and day typical price , to decide if Lineage Cell Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.63 |
Good predictability
Lineage Cell Therapeutics has good predictability. Overlapping area represents the amount of predictability between Lineage Cell time series from 10th of June 2023 to 6th of March 2024 and 6th of March 2024 to 1st of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Lineage Cell Therapeutics price movement. The serial correlation of 0.63 indicates that roughly 63.0% of current Lineage Cell price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.63 | |
| Spearman Rank Test | 0.64 | |
| Residual Average | 0.0 | |
| Price Variance | 4555.31 |
Lineage Cell Therapeutics lagged returns against current returns
Autocorrelation, which is Lineage Cell stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Lineage Cell's stock expected returns. We can calculate the autocorrelation of Lineage Cell returns to help us make a trade decision. For example, suppose you find that Lineage Cell has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Lineage Cell regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Lineage Cell stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Lineage Cell stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Lineage Cell stock over time.
Current vs Lagged Prices |
| Timeline |
Lineage Cell Lagged Returns
When evaluating Lineage Cell's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Lineage Cell stock have on its future price. Lineage Cell autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Lineage Cell autocorrelation shows the relationship between Lineage Cell stock current value and its past values and can show if there is a momentum factor associated with investing in Lineage Cell Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Lineage Stock
When determining whether Lineage Cell Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lineage Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lineage Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lineage Cell Therapeutics Stock:Check out Lineage Cell Correlation, Lineage Cell Volatility and Lineage Cell Alpha and Beta module to complement your research on Lineage Cell. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Lineage Cell technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.